EVFM Evofem Biosciences Inc.

6.6
0  0%
Previous Close 6.6
Open
Price To Book -10.64
Market Cap 306,756,793
Shares 46,478,302
Volume 0
Short Ratio
Av. Daily Volume 107,537

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due fall of 2019.
Amphora - AMPREVENCE
Prevention of urogenital Chlamydia trachomatis infection in women
Phase 3 data released December 17, 2018. Primary endpoint met. NDA to be refiled 2H 2019.
Amphora - AMPOWER
contraceptive vaginal gel

Latest News

  1. Evofem Biosciences Closes $80 Million Financing Transaction with PDL BioPharma and Other Long-time Investors
  2. PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts
  3. Evofem Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference
  4. PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y
  5. PDL Biopharma Inc (PDLI) Q1 2019 Earnings Call Transcript
  6. Evofem Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update
  7. Evofem Biosciences to Report First Quarter 2019 Results and Provide Corporate Update on May 7, 2019
  8. Evofem Biosciences Announces Last Patient Enrolled for AMPREVENCE, the Phase 2b Sexually Transmitted Infections Trial of Amphora
  9. STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Evofem Biosciences, Inc. – EVFM
  10. PDL BioPharma Announces Equity Investment in Evofem Biosciences
  11. Evofem Biosciences Enters into Financing Agreement for up to $80 Million, Closes First Tranche of Strategic Investment from PDL BioPharma
  12. Evofem Biosciences to Present at Needham Healthcare Conference
  13. Evofem Biosciences to Present at Upcoming Investor Conferences
  14. Edited Transcript of EVFM earnings conference call or presentation 1-Mar-19 4:00pm GMT
  15. Evofem Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
  16. Evofem Biosciences to Report Fourth Quarter and Year-end 2018 Results and Provide Corporate Update on March 1, 2019
  17. Evofem Biosciences, Amphora a Potential New Birth Control, Analysts Review and Target
  18. Evofem Biosciences Provides Corporate Update and Announces Upcoming Milestones
  19. Edited Transcript of EVFM earnings conference call or presentation 7-Nov-18 4:00pm GMT